NI201200027A - Anticuerpos contra el exto - Google Patents

Anticuerpos contra el exto

Info

Publication number
NI201200027A
NI201200027A NI201200027A NI201200027A NI201200027A NI 201200027 A NI201200027 A NI 201200027A NI 201200027 A NI201200027 A NI 201200027A NI 201200027 A NI201200027 A NI 201200027A NI 201200027 A NI201200027 A NI 201200027A
Authority
NI
Nicaragua
Prior art keywords
erbb3
antibodies
antigen
receptor
binding fragments
Prior art date
Application number
NI201200027A
Other languages
English (en)
Spanish (es)
Inventor
Schoeberl Birgit
Nielsen Ulrik
Feldhaus Michael
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201200027(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of NI201200027A publication Critical patent/NI201200027A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NI201200027A 2009-08-21 2012-02-15 Anticuerpos contra el exto NI201200027A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21

Publications (1)

Publication Number Publication Date
NI201200027A true NI201200027A (es) 2013-01-29

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201200027A NI201200027A (es) 2009-08-21 2012-02-15 Anticuerpos contra el exto

Country Status (21)

Country Link
EP (1) EP2467164A2 (fr)
JP (1) JP5752687B2 (fr)
KR (1) KR20120059568A (fr)
CN (1) CN103002912A (fr)
AU (1) AU2010284018C1 (fr)
BR (1) BR112012003809A2 (fr)
CA (1) CA2771744A1 (fr)
CR (1) CR20120108A (fr)
DO (1) DOP2012000044A (fr)
EA (1) EA201200195A1 (fr)
EC (1) ECSP12011740A (fr)
IL (1) IL218097A0 (fr)
IN (1) IN2012DN01518A (fr)
MA (1) MA33582B1 (fr)
MX (1) MX336091B (fr)
NI (1) NI201200027A (fr)
PE (1) PE20121585A1 (fr)
SG (1) SG178509A1 (fr)
TN (1) TN2012000057A1 (fr)
WO (1) WO2011022727A2 (fr)
ZA (1) ZA201201195B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
BR112012012160B1 (pt) 2009-11-13 2022-04-26 Amgen, Inc. Material e métodos para tratar ou prevenir doenças associadas ao her-3
PH12012501157A1 (en) 2009-12-22 2012-10-29 Roche Glycart Ag Anti-her3 antibodies and uses thereof
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
US8481687B2 (en) 2010-04-09 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
SG187908A1 (en) 2010-08-20 2013-03-28 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IT1402149B1 (it) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
KR101862832B1 (ko) 2010-11-01 2018-05-30 심포젠 에이/에스 Ｐａｎ―ｈｅｒ 항체 조성물
BR112013027021A2 (pt) 2011-04-19 2016-11-29 Merrimack Pharmaceuticals Inc anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
KR20140033152A (ko) * 2011-06-20 2014-03-17 교와 핫꼬 기린 가부시키가이샤 항erbB3 항체
PH12014500483A1 (en) 2011-09-30 2014-04-14 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
AU2012318541B2 (en) 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
JP6149042B2 (ja) * 2011-11-09 2017-06-14 ザ ユーエービー リサーチ ファンデーション Ｈｅｒ３抗体およびその使用
KR102083957B1 (ko) 2011-12-05 2020-03-04 노파르티스 아게 표피 성장 인자 수용체 3 (her3)에 대한 항체
US20150037336A1 (en) * 2012-02-22 2015-02-05 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015058108A1 (fr) * 2013-10-17 2015-04-23 Sanford-Burnham Medical Research Institute Biomarqueurs de la sensibilité à des médicaments et procédé d'identification et d'utilisation desdits biomarqueurs de la sensibilité à des médicaments
EP3087394A2 (fr) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
EP3786186A1 (fr) 2014-02-28 2021-03-03 Merus N.V. Anticorps qui se lient aux egfr et erbb3
CN110642952B (zh) * 2014-08-14 2021-05-25 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
WO2016038609A1 (fr) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anticorps anti-her3 et leurs utilisations
WO2016038610A1 (fr) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions et procédés de traitement d'un cancer résistant à un inhibiteur de la tyrosine kinase (tki)
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017069628A2 (fr) 2015-10-23 2017-04-27 Merus N.V. Molécules de liaison inhibant la croissance de cancer
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
US12195551B2 (en) 2017-05-17 2025-01-14 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
SI3665198T1 (sl) 2017-08-09 2025-06-30 Merus N.V. Protitelesa, ki vežejo egfr in cmet
US11390686B2 (en) 2017-08-09 2022-07-19 University Of Saskatchewan HER3 binding agents and uses thereof
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
JP2021534811A (ja) * 2018-06-22 2021-12-16 シーアールディー ファーマシューティカルズ インコーポレイティド 抗ｈｅｒ３抗体およびその用途
CN122011191A (zh) * 2020-10-14 2026-05-12 苏州盛迪亚生物医药有限公司 抗her3抗体和抗her3抗体药物偶联物及其医药用途
KR20230128271A (ko) * 2020-11-20 2023-09-04 악티늄 파마슈티컬즈, 인코포레이티드 고형 암의 치료를 위한 her3 방사선면역요법
IL309337A (en) * 2021-06-15 2024-02-01 Beijing Sinotau Bio Pharmaceuticals Tech Co Ltd Anti-HER3 antibody, anti-HER3 antibody-drug conjugate and uses thereof
WO2023198138A1 (fr) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 Anticorps ou fragment de liaison à l'antigène de celui-ci et son utilisation médicale

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178789A1 (en) * 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof

Also Published As

Publication number Publication date
AU2010284018B2 (en) 2014-06-05
IL218097A0 (en) 2012-04-30
WO2011022727A2 (fr) 2011-02-24
MA33582B1 (fr) 2012-09-01
ECSP12011740A (es) 2013-02-28
EA201200195A1 (ru) 2012-12-28
CN103002912A (zh) 2013-03-27
DOP2012000044A (es) 2012-06-30
MX2012002172A (es) 2012-05-29
AU2010284018A1 (en) 2012-03-22
AU2010284018C1 (en) 2015-10-15
KR20120059568A (ko) 2012-06-08
WO2011022727A3 (fr) 2013-06-27
BR112012003809A2 (pt) 2019-09-24
JP5752687B2 (ja) 2015-07-22
ZA201201195B (en) 2015-07-29
TN2012000057A1 (en) 2013-09-19
EP2467164A2 (fr) 2012-06-27
CR20120108A (es) 2012-06-05
MX336091B (es) 2016-01-08
CA2771744A1 (fr) 2011-02-24
JP2013506622A (ja) 2013-02-28
IN2012DN01518A (fr) 2015-06-05
SG178509A1 (en) 2012-04-27
PE20121585A1 (es) 2012-11-29

Similar Documents

Publication Publication Date Title
ECSP12011740A (es) Anticuerpos contra el extodominio de erbb3 y usos de los mismos
ECSP099637A (es) Anticuerpos contra el erbb3 y los usos de los mismos
CY1119154T1 (el) Anti-vla-4 αντισωματα
TR201905458T4 (tr) Fap ve dr5 için spesifik bispesifik antikorlar, dr5 için spesifik antikorlar ve bunların kullanım yöntemleri.
CY1118761T1 (el) Αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης 3 (her3)
CR20140146A (es) Anticuerpos anti-cd134 (ox40) y usos de los mismos
CR20150493A (es) Composiciones de amri contra el componente c5 del complemento y métodos para su uso
MX369740B (es) Anticuerpos contra claudina 18.2 útiles en el diagnóstico de cáncer.
MX377710B (es) Anticuerpos monoclonales contra bcma.
CL2017002641A1 (es) Construcciones de anticuerpos biespecíficos contra cdh3 y cd3
MX2016009954A (es) Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd).
CR20150634A (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
BR112016014966A2 (pt) Anticorpos e fragmentos anti-vista
ECSP12011583A (es) Compuestos que modulan selectivamente el receptor CB2.
WO2018151841A8 (fr) Molécules de liaison multispécifiques ayant une spécificité vis-à-vis du dystroglycane et de la laminine-2
EP3370783C0 (fr) Agrégats cellulosiques hémostatiques compactés
CO7151529A2 (es) Anticuerpos anti-cd22 e inmunoconjugados
CU20140073A7 (es) Composiciones y métodos para anticuerpos que actúan sobre el factor p
EP3705494A3 (fr) Anticorps contre les protéines frizzled et leurs méthodes d'utilisation
CO7240413A2 (es) Composición farmacéutica que comprende fimasartan e hidroclorotiazida
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
BR112017002755A2 (pt) anticorpos direcionados contra o receptor fc gama iib e o receptor fc épsilon
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
EP3589320A4 (fr) Anticorps ayant subi une mutation de cystéine pour conjugaison